/PRNewswire/ Amgen (NASDAQ:AMGN) today outlined its growth strategy through 2030, a period during which the Company expects to deliver attractive financial.
/PRNewswire/ Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2021 versus comparable periods in 2020. Key results.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive,.
/PRNewswire/ Amgen (NASDAQ: AMGN) today announced that LUMAKRAS® (sotorasib) has been approved in Japan for the treatment of KRAS G12C-mutated positive,.